India Proposes Stronger Controls for Medicine Storage and Distribution
The Health Ministry has proposed bringing Good Storage and Distribution Practices into the Drugs Rules, aiming to improve traceability and protect medicines as they move through the supply chain.
The Union Health Ministry has proposed adding Good Storage and Distribution Practices (GSDP) for pharmaceutical products to the Drugs Rules, 1945, in a move aimed at strengthening oversight of medicines after they leave manufacturing facilities. The proposal would extend quality safeguards across procurement, warehousing, transportation and distribution, with the stated objective of preserving a medicine’s quality and identity until it reaches a patient or healthcare provider.
What the proposed framework covers
The proposed requirements draw on guidance developed by the Central Drugs Standard Control Organisation (CDSCO). They cover several stages of the supply chain, including purchasing, storage, distribution, transport, documentation and record-keeping. The ministry says the intention is to ensure that pharmaceutical products remain within specified quality and environmental conditions as they move between manufacturers, importers, wholesalers, distributors, stockists and other supply-chain participants.
Storage and transport conditions matter because a medicine can be exposed to heat, moisture, contamination or handling errors after it has been manufactured. A product that leaves a factory in suitable condition may not retain the same quality if it is stored or transported improperly. The proposed framework is designed to address such risks through clearer procedures and stronger accountability.
Traceability and responsibility across the supply chain
The ministry says the proposed rules are intended to improve documentation and traceability while supporting inspection and enforcement by Central and State drug-control authorities. That would make it more important for businesses involved in distribution to maintain records showing how products were procured, stored, moved and supplied.
The framework also seeks to reduce risks such as deterioration, contamination, product mix-ups, falsification, diversion and unauthorised distribution. These are distinct problems, but each can undermine confidence in the quality and identity of medicines. Better records and defined handling practices can help regulators and companies identify where a problem occurred and which parts of a supply chain may need corrective action.
The proposal is not yet a final rule
The announcement describes a proposed incorporation of GSDP guidelines into the Drugs Rules, rather than a completed change already in force. The ministry has invited stakeholders and members of the public to submit objections and suggestions to its Drugs Regulation division. The proposal is therefore subject to the regulatory process, and the final requirements and implementation details should be checked against the eventual notification.
Pharmaceutical industry publication PharmaBiz reported on the draft amendment on November 19, describing the proposal as an effort to give the distribution-practice guidance a formal place in the regulatory framework. The ministry’s statement provides the broader policy rationale and identifies the stages of the supply chain that the proposed practices are intended to cover.
What it could mean for patients and businesses
For patients, the central issue is whether medicines retain their quality between production and supply. Stronger controls could support that objective by encouraging consistent storage conditions, safer transport, reliable documentation and clearer responsibility when products pass between businesses. The proposal does not, by itself, establish that every medicine currently in circulation is unsafe or that a particular product has been affected.
For manufacturers, importers, wholesalers and distributors, formalising the guidance in the Drugs Rules could increase the importance of documented procedures, staff training, suitable facilities and records that can be examined during regulatory inspections. Smaller supply-chain operators may need to assess whether their current storage and transport arrangements meet any final requirements.
The next significant step will be the consideration of feedback and the publication of any final amendment. Until then, the ministry’s announcement should be understood as a proposal to strengthen medicine-handling standards, not as a statement that the new obligations have already taken effect.
Sources
Written with automated tools from the sources above and published without editor review. Spotted an error? Tell us · Corrections Policy
Related stories

Apple opens US research programme to test how people interpret health AI answers
Apple and OpenEvidence have launched a US research study that will examine how up to 200,000 adults use conversational health AI, assess its answers and understand clinical information.

Apple opens US study to examine how people understand and trust health AI
Apple and OpenEvidence have launched a US research study that will examine how up to 200,000 adults use conversational health AI, assess its answers and understand clinical information.

ICMR Turns a Century of Health Research Innovations Into Industry Partnerships
The Indian Council of Medical Research says it has completed 100 technology-transfer deals in under two years. At its November research summit, it exchanged 20 licensing agreements covering eight technologies with nine Indian companies and unveiled new research, surveillance and training initiatives.

US loses measles elimination status after 26 years
The Pan American Health Organization has ruled measles endemic again in the United States, Mexico and Bolivia, after a year of continuous spread and the country's worst outbreak in decades.
